Craig at Segue Ventures, the PR/Marketing firm for PLRS says that much of the additional shares issued are "restricted" from wholesale trading in the market right now. That means that the effective "float" may be only about 500M shares. Most of the "restricted" shares will not be available for trading for a year. Other restrictions on PLRS shares that were part of the financing deal relate to "trickle" selling...that is, the NUMBER of shares that CAN be sold are limited as to the pps/volume.
Nonetheless, it is EXTREMELY disturbing to see a virtual 66% decline in pps from the high only a few months ago. This huge sale can not be totally explained by the dilutive effects of the recent stock issuance for financing deal.
Segue maintains that PLRS has one of THE BEST business plans that they have seen in a developmental bio-tech company.
My problem is that all of my "average down" funds have been nearly exhausted!! <Tonbo frowns>
I see a 3-5 year time horizon for PLRS pps appreciation.
My guesstimates show that PLRS earnings of only $160 Million ($.10/share) and a P/E ratio of only 10 would generate a $1.00/pps. Any better profits or improved P/E ratio would magnify the pps greatly. However, it is unlikely that any corporate profits will appear for several years.